Inhibition  ||| S:0 E:11 ||| NNP
of  ||| S:11 E:14 ||| IN
TNF-alpha  ||| S:14 E:24 ||| JJ
induced-adhesion  ||| S:24 E:41 ||| JJ
molecules  ||| S:41 E:51 ||| NNS
by  ||| S:51 E:54 ||| IN
Avène  ||| S:54 E:60 ||| NNP
Thermal  ||| S:60 E:68 ||| NNP
Spring  ||| S:68 E:75 ||| NNP
Water  ||| S:75 E:81 ||| NNP
in  ||| S:81 E:84 ||| IN
human  ||| S:84 E:90 ||| JJ
endothelial  ||| S:90 E:102 ||| FW
cells  ||| S:102 E:108 ||| FW
Cell  ||| S:108 E:113 ||| FW
adhesion  ||| S:113 E:122 ||| FW
molecules ||| S:122 E:131 ||| FW
,  ||| S:131 E:133 ||| ,
such  ||| S:133 E:138 ||| JJ
as  ||| S:138 E:141 ||| IN
E-selectin  ||| S:141 E:152 ||| JJ
or  ||| S:152 E:155 ||| CC
intercellular  ||| S:155 E:169 ||| JJ
adhesion  ||| S:169 E:178 ||| JJ
molecule  ||| S:178 E:187 ||| NN
1  ||| S:187 E:189 ||| CD
( ||| S:189 E:190 ||| -LRB-
ICAM-1 ||| S:190 E:196 ||| NNP
) ||| S:196 E:197 ||| -RRB-
,  ||| S:197 E:199 ||| ,
play  ||| S:199 E:204 ||| VB
an  ||| S:204 E:207 ||| DT
important  ||| S:207 E:217 ||| JJ
role  ||| S:217 E:222 ||| NN
in  ||| S:222 E:225 ||| IN
mediating  ||| S:225 E:235 ||| JJ
leucocyte  ||| S:235 E:245 ||| JJ
capture  ||| S:245 E:253 ||| NN
and  ||| S:253 E:257 ||| CC
rolling  ||| S:257 E:265 ||| VBG
on  ||| S:265 E:268 ||| IN
the  ||| S:268 E:272 ||| DT
surface  ||| S:272 E:280 ||| NN
of  ||| S:280 E:283 ||| IN
blood  ||| S:283 E:289 ||| NN
vessels  ||| S:289 E:297 ||| NNS
in  ||| S:297 E:300 ||| IN
atopic  ||| S:300 E:307 ||| JJ
skin ||| S:307 E:311 ||| NN
.  ||| S:311 E:313 ||| .
The  ||| S:313 E:317 ||| DT
effectiveness  ||| S:317 E:331 ||| NN
of  ||| S:331 E:334 ||| IN
Avène  ||| S:334 E:340 ||| NNP
hydrotherapy  ||| S:340 E:353 ||| NN
in  ||| S:353 E:356 ||| IN
patients  ||| S:356 E:365 ||| NNS
suffering  ||| S:365 E:375 ||| VBG
from  ||| S:375 E:380 ||| IN
atopic  ||| S:380 E:387 ||| JJ
dermatitis  ||| S:387 E:398 ||| NN
has  ||| S:398 E:402 ||| VBZ
previously  ||| S:402 E:413 ||| RB
been  ||| S:413 E:418 ||| VBN
demonstrated ||| S:418 E:430 ||| VBN
.  ||| S:430 E:432 ||| .
Thus ||| S:432 E:436 ||| RB
,  ||| S:436 E:438 ||| ,
we  ||| S:438 E:441 ||| PRP
examined  ||| S:441 E:450 ||| VBD
the  ||| S:450 E:454 ||| DT
effect  ||| S:454 E:461 ||| NN
of  ||| S:461 E:464 ||| IN
Avène  ||| S:464 E:470 ||| NNP
Thermal  ||| S:470 E:478 ||| NNP
Spring  ||| S:478 E:485 ||| NNP
Water  ||| S:485 E:491 ||| NNP
( ||| S:491 E:492 ||| -LRB-
TSW ||| S:492 E:495 ||| NNP
)  ||| S:495 E:497 ||| -RRB-
on  ||| S:497 E:500 ||| IN
adhesion  ||| S:500 E:509 ||| JJ
molecules  ||| S:509 E:519 ||| NNS
to  ||| S:519 E:522 ||| TO
understand  ||| S:522 E:533 ||| VB
its  ||| S:533 E:537 ||| PRP$
mechanism  ||| S:537 E:547 ||| NN
of  ||| S:547 E:550 ||| IN
action ||| S:550 E:556 ||| NN
.  ||| S:556 E:558 ||| .
Human  ||| S:558 E:564 ||| JJ
endothelial  ||| S:564 E:576 ||| JJ
cells  ||| S:576 E:582 ||| NNS
EA.hy926  ||| S:582 E:591 ||| RB
were  ||| S:591 E:596 ||| VBD
treated  ||| S:596 E:604 ||| VBN
with  ||| S:604 E:609 ||| IN
tumour  ||| S:609 E:616 ||| FW
necrosis  ||| S:616 E:625 ||| FW
factor-α  ||| S:625 E:634 ||| FW
( ||| S:634 E:635 ||| -LRB-
TNFα ||| S:635 E:639 ||| NNP
)  ||| S:639 E:641 ||| -RRB-
in  ||| S:641 E:644 ||| IN
the  ||| S:644 E:648 ||| DT
presence  ||| S:648 E:657 ||| NN
or  ||| S:657 E:660 ||| CC
not  ||| S:660 E:664 ||| RB
of  ||| S:664 E:667 ||| IN
Avène  ||| S:667 E:673 ||| NNP
TSW  ||| S:673 E:677 ||| NNP
during  ||| S:677 E:684 ||| IN
4  ||| S:684 E:686 ||| CD
h ||| S:686 E:687 ||| NNS
.  ||| S:687 E:689 ||| .
As  ||| S:689 E:692 ||| IN
nuclear  ||| S:692 E:700 ||| JJ
factor-κB  ||| S:700 E:710 ||| NN
( ||| S:710 E:711 ||| -LRB-
NF-κB ||| S:711 E:716 ||| NNP
)  ||| S:716 E:718 ||| -RRB-
is  ||| S:718 E:721 ||| VBZ
involved  ||| S:721 E:730 ||| VBN
in  ||| S:730 E:733 ||| IN
the  ||| S:733 E:737 ||| DT
signalisation  ||| S:737 E:751 ||| NN
of  ||| S:751 E:754 ||| IN
inflammatory  ||| S:754 E:767 ||| JJ
mediators  ||| S:767 E:777 ||| JJ
such  ||| S:777 E:782 ||| JJ
as  ||| S:782 E:785 ||| IN
the  ||| S:785 E:789 ||| DT
adhesion  ||| S:789 E:798 ||| JJ
molecules ||| S:798 E:807 ||| NNS
,  ||| S:807 E:809 ||| ,
the  ||| S:809 E:813 ||| DT
translocation  ||| S:813 E:827 ||| NN
of  ||| S:827 E:830 ||| IN
NF-κB  ||| S:830 E:836 ||| JJ
in  ||| S:836 E:839 ||| IN
endothelial  ||| S:839 E:851 ||| JJ
cells  ||| S:851 E:857 ||| NNS
was  ||| S:857 E:861 ||| VBD
assessed  ||| S:861 E:870 ||| VBN
by  ||| S:870 E:873 ||| IN
immunohistochemistry  ||| S:873 E:894 ||| NN
with  ||| S:894 E:899 ||| IN
anti-NF-κBp65 ||| S:899 E:912 ||| CD
.  ||| S:912 E:914 ||| .
The  ||| S:914 E:918 ||| DT
protein  ||| S:918 E:926 ||| NN
and  ||| S:926 E:930 ||| CC
mRNA  ||| S:930 E:935 ||| JJ
levels  ||| S:935 E:942 ||| NNS
of  ||| S:942 E:945 ||| IN
TNFα-induced  ||| S:945 E:958 ||| NNP
ICAM-1  ||| S:958 E:965 ||| NNP
and  ||| S:965 E:969 ||| CC
E-selectin  ||| S:969 E:980 ||| NNP
were  ||| S:980 E:985 ||| VBD
assessed  ||| S:985 E:994 ||| VBN
by  ||| S:994 E:997 ||| IN
ELISA  ||| S:997 E:1003 ||| NNP
assay  ||| S:1003 E:1009 ||| NN
and  ||| S:1009 E:1013 ||| CC
RT-PCR ||| S:1013 E:1019 ||| JJ
.  ||| S:1019 E:1021 ||| .
These  ||| S:1021 E:1027 ||| DT
adhesion  ||| S:1027 E:1036 ||| JJ
molecules  ||| S:1036 E:1046 ||| NNS
were  ||| S:1046 E:1051 ||| VBD
also  ||| S:1051 E:1056 ||| RB
detected  ||| S:1056 E:1065 ||| VBN
by  ||| S:1065 E:1068 ||| IN
immunohistochemistry ||| S:1068 E:1088 ||| NN
.  ||| S:1088 E:1090 ||| .
Tumour  ||| S:1090 E:1097 ||| FW
necrosis  ||| S:1097 E:1106 ||| FW
factor-α  ||| S:1106 E:1115 ||| FW
induced  ||| S:1115 E:1123 ||| FW
the  ||| S:1123 E:1127 ||| DT
activation  ||| S:1127 E:1138 ||| NN
of  ||| S:1138 E:1141 ||| IN
p65  ||| S:1141 E:1145 ||| CD
NF-κB  ||| S:1145 E:1151 ||| JJ
nuclear  ||| S:1151 E:1159 ||| JJ
translocation ||| S:1159 E:1172 ||| NN
.  ||| S:1172 E:1174 ||| .
TNFα  ||| S:1174 E:1179 ||| NNP
also  ||| S:1179 E:1184 ||| RB
induced  ||| S:1184 E:1192 ||| VBN
E-selectin  ||| S:1192 E:1203 ||| JJ
and  ||| S:1203 E:1207 ||| CC
ICAM-1  ||| S:1207 E:1214 ||| CD
in  ||| S:1214 E:1217 ||| IN
a  ||| S:1217 E:1219 ||| DT
dose-dependant  ||| S:1219 E:1234 ||| JJ
manner  ||| S:1234 E:1241 ||| NN
in  ||| S:1241 E:1244 ||| IN
EA.hy926  ||| S:1244 E:1253 ||| CD
endothelial  ||| S:1253 E:1265 ||| CD
cells ||| S:1265 E:1270 ||| NNS
.  ||| S:1270 E:1272 ||| .
In  ||| S:1272 E:1275 ||| IN
the  ||| S:1275 E:1279 ||| DT
presence  ||| S:1279 E:1288 ||| NN
of  ||| S:1288 E:1291 ||| IN
Avène  ||| S:1291 E:1297 ||| NNP
TSW ||| S:1297 E:1300 ||| NNP
,  ||| S:1300 E:1302 ||| ,
a  ||| S:1302 E:1304 ||| DT
significant  ||| S:1304 E:1316 ||| JJ
inhibition  ||| S:1316 E:1327 ||| NN
of  ||| S:1327 E:1330 ||| IN
the  ||| S:1330 E:1334 ||| DT
TNFα-induced  ||| S:1334 E:1347 ||| JJ
E-selectin  ||| S:1347 E:1358 ||| JJ
and  ||| S:1358 E:1362 ||| CC
ICAM-1  ||| S:1362 E:1369 ||| CD
expression  ||| S:1369 E:1380 ||| NN
( ||| S:1380 E:1381 ||| -LRB-
-22 ||| S:1381 E:1384 ||| NNP
%  ||| S:1384 E:1386 ||| NN
and  ||| S:1386 E:1390 ||| CC
-7 ||| S:1390 E:1392 ||| CD
% ||| S:1392 E:1393 ||| NN
,  ||| S:1393 E:1395 ||| ,
respectively ||| S:1395 E:1407 ||| RB
,  ||| S:1407 E:1409 ||| ,
P  ||| S:1409 E:1411 ||| NN
< ||| S:1411 E:1413 ||| SYM
0.05 ||| S:1413 E:1417 ||| CD
)  ||| S:1417 E:1419 ||| -RRB-
was  ||| S:1419 E:1423 ||| VBD
observed ||| S:1423 E:1431 ||| VBN
.  ||| S:1431 E:1433 ||| .
These  ||| S:1433 E:1439 ||| DT
data  ||| S:1439 E:1444 ||| NNS
suggest  ||| S:1444 E:1452 ||| VBP
that  ||| S:1452 E:1457 ||| IN
Avène  ||| S:1457 E:1463 ||| NNP
TSW  ||| S:1463 E:1467 ||| NNP
mediated  ||| S:1467 E:1476 ||| VBD
inhibition  ||| S:1476 E:1487 ||| VBN
of  ||| S:1487 E:1490 ||| IN
TNFα-induced  ||| S:1490 E:1503 ||| JJ
E-selectin  ||| S:1503 E:1514 ||| JJ
and  ||| S:1514 E:1518 ||| CC
ICAM-1  ||| S:1518 E:1525 ||| CD
expression ||| S:1525 E:1535 ||| NN
.  ||| S:1535 E:1537 ||| .
The  ||| S:1537 E:1541 ||| DT
inhibition  ||| S:1541 E:1552 ||| NN
of  ||| S:1552 E:1555 ||| IN
such  ||| S:1555 E:1560 ||| JJ
adhesion  ||| S:1560 E:1569 ||| JJ
molecules  ||| S:1569 E:1579 ||| NN
is  ||| S:1579 E:1582 ||| VBZ
attributable  ||| S:1582 E:1595 ||| JJ
to  ||| S:1595 E:1598 ||| TO
the  ||| S:1598 E:1602 ||| DT
suppression  ||| S:1602 E:1614 ||| NN
of  ||| S:1614 E:1617 ||| IN
NF-κB  ||| S:1617 E:1623 ||| JJ
transcription  ||| S:1623 E:1637 ||| JJ
factor  ||| S:1637 E:1644 ||| NN
pathway  ||| S:1644 E:1652 ||| NN
activation ||| S:1652 E:1662 ||| NN
.  ||| S:1662 E:1664 ||| .
